Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief executive Jeremy Skillington joins Proactive London to talk through the recent preparations for the upcoming challenge study for POLB 001, its treatment for severe influenza.
He explains the significance of the recent contract signed with manufacturing partners to produce the drug to good manufacturing (GMP) standards for the influenza clinical trial, as well as how the company is also exploring the potential for it to be used to treat other diseases as well, and how that would appeal to potential partners.